355 related articles for article (PubMed ID: 26858125)
1. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer.
Sansone P; Ceccarelli C; Berishaj M; Chang Q; Rajasekhar VK; Perna F; Bowman RL; Vidone M; Daly L; Nnoli J; Santini D; Taffurelli M; Shih NN; Feldman M; Mao JJ; Colameco C; Chen J; DeMichele A; Fabbri N; Healey JH; Cricca M; Gasparre G; Lyden D; Bonafé M; Bromberg J
Nat Commun; 2016 Feb; 7():10442. PubMed ID: 26858125
[TBL] [Abstract][Full Text] [Related]
2. Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles.
Sansone P; Berishaj M; Rajasekhar VK; Ceccarelli C; Chang Q; Strillacci A; Savini C; Shapiro L; Bowman RL; Mastroleo C; De Carolis S; Daly L; Benito-Martin A; Perna F; Fabbri N; Healey JH; Spisni E; Cricca M; Lyden D; Bonafé M; Bromberg J
Cancer Res; 2017 Apr; 77(8):1927-1941. PubMed ID: 28202520
[TBL] [Abstract][Full Text] [Related]
3. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
Santiago-Gómez A; Kedward T; Simões BM; Dragoni I; NicAmhlaoibh R; Trivier E; Sabin V; Gee JM; Sims AH; Howell SJ; Clarke RB
Cancer Lett; 2019 Aug; 458():66-75. PubMed ID: 31121213
[TBL] [Abstract][Full Text] [Related]
4. FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4.
McClements L; Annett S; Yakkundi A; O'Rourke M; Valentine A; Moustafa N; Alqudah A; Simões BM; Furlong F; Short A; McIntosh SA; McCarthy HO; Clarke RB; Robson T
BMC Cancer; 2019 Apr; 19(1):351. PubMed ID: 30975104
[TBL] [Abstract][Full Text] [Related]
5. Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.
Simões BM; O'Brien CS; Eyre R; Silva A; Yu L; Sarmiento-Castro A; Alférez DG; Spence K; Santiago-Gómez A; Chemi F; Acar A; Gandhi A; Howell A; Brennan K; Rydén L; Catalano S; Andó S; Gee J; Ucar A; Sims AH; Marangoni E; Farnie G; Landberg G; Howell SJ; Clarke RB
Cell Rep; 2015 Sep; 12(12):1968-77. PubMed ID: 26387946
[TBL] [Abstract][Full Text] [Related]
6. Fascin Is Critical for the Maintenance of Breast Cancer Stem Cell Pool Predominantly via the Activation of the Notch Self-Renewal Pathway.
Barnawi R; Al-Khaldi S; Majed Sleiman G; Sarkar A; Al-Dhfyan A; Al-Mohanna F; Ghebeh H; Al-Alwan M
Stem Cells; 2016 Dec; 34(12):2799-2813. PubMed ID: 27502039
[TBL] [Abstract][Full Text] [Related]
7. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
8. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
9. High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer.
Alves CL; Elias D; Lyng M; Bak M; Kirkegaard T; Lykkesfeldt AE; Ditzel HJ
Clin Cancer Res; 2016 Nov; 22(22):5514-5526. PubMed ID: 27252418
[TBL] [Abstract][Full Text] [Related]
10. IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis.
Siersbæk R; Scabia V; Nagarajan S; Chernukhin I; Papachristou EK; Broome R; Johnston SJ; Joosten SEP; Green AR; Kumar S; Jones J; Omarjee S; Alvarez-Fernandez R; Glont S; Aitken SJ; Kishore K; Cheeseman D; Rakha EA; D'Santos C; Zwart W; Russell A; Brisken C; Carroll JS
Cancer Cell; 2020 Sep; 38(3):412-423.e9. PubMed ID: 32679107
[TBL] [Abstract][Full Text] [Related]
11. In vitro characterization of CD133
Nair RM; Balla MM; Khan I; Kalathur RKR; Kondaiah P; Vemuganti GK
BMC Cancer; 2017 Nov; 17(1):779. PubMed ID: 29162051
[TBL] [Abstract][Full Text] [Related]
12. Targeting STAT3 signaling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer.
Simões BM; Santiago-Gómez A; Chiodo C; Moreira T; Conole D; Lovell S; Alferez D; Eyre R; Spence K; Sarmiento-Castro A; Kohler B; Morisset L; Lanzino M; Andò S; Marangoni E; Sims AH; Tate EW; Howell SJ; Clarke RB
Oncogene; 2020 Jun; 39(25):4896-4908. PubMed ID: 32472077
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
14. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
[TBL] [Abstract][Full Text] [Related]
15. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
16. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
17. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
McKeage K; Curran MP; Plosker GL
Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
[TBL] [Abstract][Full Text] [Related]
18. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
19. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]